The plausibility battleground at the EPO
09-11-2020
Breaking: EPO board to refer key issues in Broad appeal to higher panel
15-01-2020
Servickuz / Shutterstock.com
Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
The invention of the antibody hybridoma technology by Nobel prize winners Georges Köhler and César Milstein in 1975 paved the way to the development of therapeutic antibodies.
The first therapeutic monoclonal antibody obtained market approval in the US in 1986. Since then the market value of therapeutic antibodies has grown to approximately $115.2 billion in 2018 and is expected to reach $300 billion in 2025.
Along with this development, the number of patent applications seeking protection for therapeutic antibodies at the European Patent Office (EPO) has constantly grown and is growing further.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
EPO, therapeutic antibodies, inventions, Vossius & Partner, prior art, CDRs, framework regions, Boards of Appeal, US Patent and Trademark Office
